Advertisement

Moderna Incorporated receives additional funds to develop COVID-19 vaccine

US-based drug maker Moderna Incorporated says it has received an additional US$472 million  from the U.S. government's Biomedical Advanced Research and Development Authority to support development of  its coronavirus vaccine.

Moderna said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of  its vaccine candidate.

In April, Moderna received $483 million  from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of  Health.

According to the company the Phase 3 study, conducted in collaboration with the National Institute of  Allergy and Infectious Diseases, will begin today and involve about 30,000 participants.

Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.



Most Popular
Regional private sector body welcomes...